LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Home・Akcijų sąrašas・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

10.8 -3.74

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.8

Max

11.31

Pagrindiniai rodikliai
By Trading Economics
Pajamos	227M
Pardavimai	139M
P/E Sektoriaus vid.	4.522 50.102
Pelno marža	163.843
Darbuotojai	1,796
EBITDA	1.3M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+43.34% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.1B
Ankstesnė atidarymo kaina	14.54
Ankstesnė uždarymo kaina	10.8

Naujienos nuotaikos

By Acuity

10%

90%

5 / 344 reitingas Healthcare

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-28 22:47; UTC

Uždarbis

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026-05-28 20:45; UTC

Uždarbis

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026-05-28 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026-05-28 23:39; UTC

Rinkos pokalbiai

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026-05-28 23:31; UTC

Rinkos pokalbiai

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026-05-28 23:17; UTC

Rinkos pokalbiai

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026-05-28 23:02; UTC

Rinkos pokalbiai

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-28 22:41; UTC

Rinkos pokalbiai

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026-05-28 22:37; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026-05-28 22:04; UTC

Įsigijimai, susijungimai, perėmimai

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026-05-28 21:12; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-28 21:00; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026-05-28 20:57; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:55; UTC

Uždarbis

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026-05-28 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-28 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-28 20:48; UTC

Karštos akcijos

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026-05-28 20:34; UTC

Uždarbis

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026-05-28 20:31; UTC

Uždarbis

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026-05-28 20:28; UTC

Uždarbis

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026-05-28 20:26; UTC

Uždarbis

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Membership Fees $1.37B

2026-05-28 20:20; UTC

Uždarbis

Costco 3Q Net Sales $69.15B

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026-05-28 20:19; UTC

Uždarbis

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026-05-28 20:17; UTC

Uždarbis

Costco 3Q Same-Store Sales Up 9.8% >COST

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

43.34% į viršų

12 mėnesių prognozė

Vidutinis 16.8 USD 43.34%

Aukščiausias 20 USD

Žemiausias 13.6 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Hutchison China MediTech Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

5 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.